Pulsewave completes its pre-seed round

Biel/Bienne based PulseWave AG is a digital health care company redefining the way arterial sclerosis is clinically diagnosed and monitored over time. Pulsewave’s flagship product, the TempleGuard, combines a wearable biosensor device worn conveniently, discreet and permanently with eyeglasses and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information.

The startup believes improvements in arterial stiffness monitoring and characterization have the potential to change clinical management of patients. In North America alone, more than 75% of people older than 55 constantly wear eyeglasses, yet there is no convenient wearable available on the market, which provides reliable and constant day-time measurements of cardiac indicators to predict the development of arterial stiffness, coronary artery disease and ischemic heart disease.

Founded in 2021, the company has a working prototype (POC), which collects data from behind the ear, transfers that data to a Smartphone App and the Smartphone transfers data to the cloud. Thanks to fresh capital from a pre-seed round, Pulsewave AG is ready to enter the development phase together with the University of Applied Sciences in Bern. The company secured a total of CHF 260’000 with the participation of Stiftung für technologische Innovation and the Canton of Bern.

Additionally, Pulsewave AG has entered an R&D partnership with the Inselspital, Bern to develop and clinically test its product, as revealed by Peter Weisz, CEO and Co-Founder of Pulsewave. The project will be financed by an Innosuisse Grant. “Furthermore, we have a partnership with Maccabi – KSM, Israels 2nd largest digital patient database. This cooperation will help us to develop our Algorithms on clinically validated real patient data. The value for our venture is tremendous”, adds Weisz.

(Press release/RAN)